Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb;8(1):167-170.
doi: 10.1002/ehf2.12758. Epub 2020 Nov 7.

Impella 5.0 supported oncological surgery as bridge to LVAD

Andrea Montisci  1   2 , Giancarlo Micheletto  3   4 , Serena Sibilio  2 , Francesco Donatelli  2   5 , Maurizio Tespili  6 , Carlo Banfi  2   5 , Francesco Casilli  6 , Daniele Cosseta  1 , Antonio Miceli  7 , Silvia Cirri  1 , Federico Pappalardo  8   9
Affiliations
Case Reports

Impella 5.0 supported oncological surgery as bridge to LVAD

Andrea Montisci et al. ESC Heart Fail. 2021 Feb.

Abstract

We describe the case of a 58-year-old man presenting with myocardial infarction complicated by cardiogenic shock, treated with Impella CP which was escalated to an axillary 5.0 due to lack of cardiac recovery. Weaning from Impella 5.0 failed, and the patient was evaluated for heart transplantation (HTx) or left ventricular assist device (LVAD). HTx was excluded because of a rectal adenocarcinoma. The patient underwent colorectal surgery while on Impella. Perioperative course was uneventful. After 61 days of Impella, when the LVAD implantation was scheduled, the patient died due to K. pneumoniae infection.

Keywords: Cancer; Cariogenic shock; Left ventricular assist device; Mechanical circulatory support; Myocardial infarction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) basal coronary angiography. (B) Chronic total occlusion of right coronary artery. (C) After left anterior descending revascularization. (D) After Impella CP implantation.
See this image and copyright information in PMC

References

    1. Beaty CA, George TJ, Kilic A, Conte JV, Shah AS. Pre‐transplant malignancy: an analysis of outcomes after thoracic organ transplantation. J Heart Lung Transplant 2013; 32: 202–211. - PMC - PubMed
    1. Samuels L, Casanova Ghosh E, Domsky S, Droogan C, Samuels M, DeNittis A, Ali Z. Beyond the means of natural selection: a case of end stage heart failure and advanced esophageal cancer successfully treated with an implantable left ventricular assist device (LVAD) and aggressive chemoradiation therapy. Cardiovasc Disord Med 2017; 2: 1–3.
    1. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, el‐Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohacsi P, Mooney M, Nelson T, Pagani F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J. International Society for Heart and Lung Transplantation. The 2013 International Society For Heart And Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013; 32: 157–187. - PubMed
    1. Glynne‐Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D. on behalf of the ESMO Guidelines CommitteeRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol 2017; 28: 22–40. - PubMed
    1. Van De Car DA, Sunil V, Rao E. Magnus Ohman (2010) Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther 2010; 8: 1673–1681. - PubMed

Publication types

LinkOut - more resources